Risk of Systemic Adverse Events after Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Routine Clinical Practice
Written by: Joshua D. Levinson, MD November 2020 Maloney MH, Payne SR, Herrin J, et al. Risk of Systemic Adverse Events after Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Routine Clinical Practice. Ophthalmol. Published online August 2020. doi:10.1016/j.ophtha.2020.07.062 Intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents have become the standard of care in the treatment of multiple […]